• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, August 21, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Skin patch shows promise for children with milk-induced eosinophilic esophagitis

Bioengineer by Bioengineer
May 22, 2019
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Nearly half of patients saw improvements in their symptoms

IMAGE

Credit: Children’s Hospital of Philadelphia

A new study from Children’s Hospital of Philadelphia (CHOP) finds that a skin patch may be useful in treating children with a painful, chronic condition called eosinophilic esophagitis (EoE) triggered by milk. Among 20 children with EoE who wore Viaskin Milk – a skin patch measuring just over an inch long containing trace amounts of milk protein – nine (47%) saw an improvement in their symptoms and normalization of their biopsies after 11 months. This is the first study to examine how this treatment, called epicutaneous immunotherapy, may help children with milk-induced EoE.

The findings were published online this month in the journal Clinical Gastroenterology and Hepatology.

The pilot study followed 20 children aged 4 to 17 with EoE. The patients followed a milk-free diet for nine months, then re-introduced milk into their diet for the next two months. After 11 months, almost half of those wearing the Viaskin Milk patch had fewer EoE symptoms, including less inflammation when they underwent an endoscopy compared to none in the placebo group.

“This study shows great promise for an immunotherapy that aims to desensitize children to milk,” said study leader Jonathan Spergel, MD, PhD, Chief of the Allergy Program at CHOP. “Our next step would be to launch a much larger study to confirm our results. Currently, there’s no cure for EoE, so this would be the first strategy to treat the underlying cause of the disease.”

EoE is a food-based disease that causes redness, swelling and itching in the esophagus when a patient eats a food that triggers their reaction. Traditional allergy testing is not helpful. Patients may experience nausea, vomiting, or a burning sensation in the throat. If left untreated, the esophagus may narrow due to scarring. Currently, the only ways to manage EoE is to treat the symptoms with off-label topical steroids which may cause growth retardation, or to follow a restrictive diet which may be difficult for patients to follow. Children with EoE often have other allergic disorders like asthma, seasonal allergies or eczema.

Disclosure of Related Financial Interest: Jonathan M. Spergel, MD, PhD, Antonella Cianferoni, MD, PhD, Megan O. Lewis, MSN, RN, CPNP, and Terri Brown-Whitehorn, MD, have consulting agreements and clinical trial grants with DBV Technologies. Jonathan M. Spergel, MD, PhD, has stock equity with DBV Technologies.

The study sponsor (DBV Technologies) had no role in analysis or interpretation of data. They provided the Viaskin Milk Patch. Final study design was done by Jonathan M. Spergel and Antonella Cianferoni.

###

About Children’s Hospital of Philadelphia: Children’s Hospital of Philadelphia was founded in 1855 as the nation’s first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, Children’s Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. In addition, its unique family-centered care and public service programs have brought the 564-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu

Media Contact
Camillia Travia
[email protected]

Related Journal Article

http://dx.doi.org/10.1016/j.cgh.2019.05.014

Tags: Clinical TrialsImmunology/Allergies/AsthmaMedicine/HealthPediatricsPharmaceutical Science
Share13Tweet8Share2ShareShareShare2

Related Posts

blank

Combination Therapy Enhances Treatment Outcomes in Advanced Triple-Negative Breast Cancer

August 21, 2025
Ambient Documentation Technologies Alleviate Physician Burnout and Rekindle Joy in Medical Practice

Ambient Documentation Technologies Alleviate Physician Burnout and Rekindle Joy in Medical Practice

August 21, 2025

Decoding mTORC1’s Dynamic Amino Acid Control

August 21, 2025

Wearable Devices Improve Parkinson’s Medication Adjustments: Trial

August 21, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    141 shares
    Share 56 Tweet 35
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    114 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    60 shares
    Share 24 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Combination Therapy Enhances Treatment Outcomes in Advanced Triple-Negative Breast Cancer

Mount Sinai Researchers Develop First Targeted Therapy for Rare T-Cell Lymphoma Following CAR T Treatment

The Evolution of Metalenses: From Single Devices to Integrated Arrays

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.